View More View Less
  • 1 Semmelweis University Clinical and Research Center for Molecular Neurology, Faculty of Medicine Tömő utca 25-29 H-1083 Budapest Hungary
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $752.00

Clopidogrel is an inhibitor of platelet-aggregation used in the prevention of secondary stroke. The molecule is activated by the cytochrome P450 2C19 (CYP2C19) enzyme. The frequent CYP2C19*2 point mutation causes loss of enzyme function, a decreased (heterozygous form) or blocked (homozygous form) formation of the active molecule. Thus, for a patient harboring a mutated allele, clopidogrel does not provide effective protection against stroke. Multiple drugs inhibit the CYP2C19 enzyme and their simultaneous use with clopidogrel is especially hazardous for patients with genetically decreased enzyme activity. Frequency of the CYP2C19*2 is variable in different populations, highest rates were detected in some Asian groups. In our study the CYP2C19 genotype was determined in one Hungarian sample of 354 stroke patients and 221 healthy controls. Frequency of the minor allele was found to be 12.87% (12.85% in stroke patients, 12.89% in healthy controls). The proportion of the homozygous CYP2C19*2 variant causing total loss of gene function was 1.74%, rate of the heterozygous allele causing reduced enzyme activity was 22.26% in the total population. Our results for the allele frequencies of the CYP2C19*2 gene are similar to those found in other Caucasian populations. In conclusion, the homozygous mutation, causing ineffectiveness of clopidogrel is relatively rare. However, the heterozygous form in which interaction of CYP2C19 inhibitors causes further decrease in the genetically impaired enzyme activity is present in every fifth drug-taking patient. Based on our findings, we would like to emphasize that it is important to adjust individually antiplatelet treatment in ischemic stroke patients and to take into consideration genetic factors as well as drugs taken for comorbid conditions.

  • Adithan C, Gerard N, Vasu S, Rosemary J, Shashindran CH, Krishnamoorthy R: Allele and genotype frequency of CYP2C19 in a Tamilian population. Br. J. Clin. Pharmacol. 56(3), 331–333 (2003)

    Krishnamoorthy R. , 'Allele and genotype frequency of CYP2C19 in a Tamilian population ' (2003 ) 56 Br. J. Clin. Pharmacol. : 331 -333.

    • Search Google Scholar
  • Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y: Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br. J. Clin. Pharmacol. 56(6), 653–657 (2003)

    Horsmans Y. , 'Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations ' (2003 ) 56 Br. J. Clin. Pharmacol. : 653 -657.

    • Search Google Scholar
  • Aynacioglu AS, Brockmoller J, Bauer S et al.: Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br. J. Clin. Pharmacol. 48(3), 409–415 (1999)

    Bauer S. , 'Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin ' (1999 ) 48 Br. J. Clin. Pharmacol. : 409 -415.

    • Search Google Scholar
  • Bhatt DL, Topol EJ: Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and dosing of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am. Heart. J. 148(2), 263–268 (2004)

    Topol E.J. , 'Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and dosing of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial ' (2004 ) 148 Am. Heart. J. : 263 -268.

    • Search Google Scholar
  • Bozina N, Granic P, Lalic Z, Tramisak I, Lovric M, Stavljenic-Rukavina A: Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19 and CYP2D6 in Croatian population. Croat. Med. J. 44(4), 425–428 (2003)

    Stavljenic-Rukavina A. , 'Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19 and CYP2D6 in Croatian population ' (2003 ) 44 Croat. Med. J. : 425 -428.

    • Search Google Scholar
  • Bravo-Villata HV, Yamamoto K, Nakamura K, Baya A, Okada Y, Horiuchi R: Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. Eur. J. Clin. Pharmacol. 61(3), 179–184 (2005)

    Horiuchi R. , 'Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study ' (2005 ) 61 Eur. J. Clin. Pharmacol. : 179 -184.

    • Search Google Scholar
  • CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 348(9038), 1329 (1996)

    'A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) ' (1996 ) 348 Lancet : 1329 -.

    • Search Google Scholar
  • Chen Z, Jiang L, Chen Y et al.: Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet. 366(9497), 1607–1621 (2005)

    Chen Y. , 'Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: Randomised placebo-controlled trial ' (2005 ) 366 Lancet : 1607 -1621.

    • Search Google Scholar
  • Gaikovitch EA, Cascorbi I, Mrozikiewicz PM et al.: Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur. J. Clin. Pharmacol. 59(4), 303–312 (2003)

    Mrozikiewicz P.M. , 'Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population ' (2003 ) 59 Eur. J. Clin. Pharmacol. : 303 -312.

    • Search Google Scholar
  • Geisler T, Langer H, Wydymus M et al.: Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Europ. Heart J. 27(20), 2420–2425 (2006)

    Wydymus M. , 'Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation ' (2006 ) 27 Europ. Heart J. : 2420 -2425.

    • Search Google Scholar
  • Goldstein JA, Ishizaki T, Chiba K et al.: Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7(1), 59–64 (1997)

    Chiba K. , 'Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations ' (1997 ) 7 Pharmacogenetics : 59 -64.

    • Search Google Scholar
  • He N, Yan FX, Huang SL et al.: CYP2C19 genotype and S-mephenytoin 4’-hydroxylation phenotype in a Chinese Dai population. Eur. J. Clin. Pharmacol. 58(1), 15–18 (2002)

    Huang S.L. , 'CYP2C19 genotype and S-mephenytoin 4’-hydroxylation phenotype in a Chinese Dai population ' (2002 ) 58 Eur. J. Clin. Pharmacol. : 15 -18.

    • Search Google Scholar
  • Jose R, Chandrasekaran A, Sam SS, et al.: CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam. Clin. Pharmacol. 19(1), 101–105 (2005)

    Sam S.S. , 'CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population ' (2005 ) 19 Fundam. Clin. Pharmacol. : 101 -105.

    • Search Google Scholar
  • Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S: Genetic polymorphism of cytochrome P450s, CYP2C9, and CYP2C19 in a Japanese population. Ther. Drug Monit. 20(3), 243–247 (1998)

    Higuchi S. , 'Genetic polymorphism of cytochrome P450s, CYP2C9, and CYP2C19 in a Japanese population ' (1998 ) 20 Ther. Drug Monit. : 243 -247.

    • Search Google Scholar
  • Lamba KJ, Dhiman RK, Kohli KK: Genetic polymorphism of the hepatic cytochrome P450 2C19 in North Indian subjects. Clin. Pharmacol. Ther. 63(4), 422–427 (1998)

    Kohli K.K. , 'Genetic polymorphism of the hepatic cytochrome P450 2C19 in North Indian subjects ' (1998 ) 63 Clin. Pharmacol. Ther. : 422 -427.

    • Search Google Scholar
  • Mehta SR, Yusuf S, Peters RJG et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. The Lancet 358(9281), 527–533 (2001)

    Peters R.J.G. , 'Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study ' (2001 ) 358 The Lancet : 527 -533.

    • Search Google Scholar
  • Sabatine MS, Cannon CP, Gibson CM et al.: Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY Study. JAMA 294, 1224–1232 (2005)

    Gibson C.M. , 'Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY Study ' (2005 ) 294 JAMA : 1224 -1232.

    • Search Google Scholar
  • Scordo MG, Caputi AP, D’Arrigo C, Fava G, Spina E: Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol. Res. 50(2), 195–200 (2004)

    Spina E. , 'Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population ' (2004 ) 50 Pharmacol. Res. : 195 -200.

    • Search Google Scholar
  • Sviri S, Shpizen S, Leitersdorf E, Levy M, Caraco Y: Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population. Clin. Pharmacol. Ther. 65(3), 275–282 (1999)

    Caraco Y. , 'Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population ' (1999 ) 65 Clin. Pharmacol. Ther. : 275 -282.

    • Search Google Scholar
  • Tamminga WJ, Wemer J, Oosterhuis B, de Zeeuw RA, de Leij LF, Jonkman JH: The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur. J. Clin. Pharmacol. 57(10), 717–722 (2001)

    Jonkman J.H. , 'The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers ' (2001 ) 57 Eur. J. Clin. Pharmacol. : 717 -722.

    • Search Google Scholar
  • U.S. Food and Drug Administration. Information for healthcare professionals: Update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC) (2009)

  • Xie HG, Kim RB, Stein CM, Wilkinson GR, Wood AJ: Genetic polymorphism of (S)-mephenytoin 4′-hydroxylation in populations of African descent. Br. J. Clin. Pharmacol. 48(3), 402–408 (1999)

    Wood A.J. , 'Genetic polymorphism of (S)-mephenytoin 4′-hydroxylation in populations of African descent ' (1999 ) 48 Br. J. Clin. Pharmacol. : 402 -408.

    • Search Google Scholar

The author instruction is available in PDF.

Please, download the file from HERE

Senior editors

Editor(s)-in-Chief: Rosivall, László

Honorary Editor(s)-in-Chief): Monos, Emil

Managing Editor(s): Bartha, Jenő; Berhidi, Anna

Co-editor(s): Koller, Ákos; Lénárd, László; Szénási, Gábor

Assistant Editor(s): G. Dörnyei (Budapest), Zs. Miklós (Budapest), Gy. Nádasy (Budapest)

Hungarian Editorial Board

      Benedek, György (Szeged)
      Benyó, Zoltán (Budapest)
      Boros, Mihály (Szeged)
      Chernoch, László (Debrecen)
      Détári, László (Budapest)
      Hamar, János (Budapest)
      Hantos, Zoltán (Szeged)
      Hunyady, László (Budapest)
      Imre, Sándor (Debrecen)
      Jancsó, Gábor (Szeged)
      Karádi, Zoltán (Pécs)
      Kovács, László (Debrecen)
      Palkovits, Miklós (Budapest)
      Papp, Gyula (Szeged)
      Pavlik, Gábor (Budapest)
      Spät, András (Budapest)
      Szabó, Gyula (Szeged)
      Szelényi, Zoltán (Pécs)
      Szolcsányi, János (Pécs)
      Szollár, Lajos (Budapest)
      Szücs, Géza (Debrecen)
      Telegdy, Gyula (Szeged)
      Toldi, József (Szeged)
      Tósaki, Árpád (Debrecen)

International Editorial Board

      R. Bauer (Jena)
      W. Benjelloun (Rabat)
      A. W. Cowley Jr. (Milwaukee)
      D. Djuric (Belgrade)
      C. Fry (London)
      S. Greenwald (London)
      O. Hänninen (Kuopio)
      H. G. Hinghofer-Szalkay (Graz)
      Th. Kenner (Graz)
      Gy. Kunos (Richmond)
      M. Mahmoudian (Tehran)
      T. Mano (Seki, Gifu)
      G. Navar (New Orleans)
      H. Nishino (Nagoya)
      O. Petersen (Liverpool)
      U. Pohl (Münich)
      R. S. Reneman (Maastricht)
      A. Romanovsky (Phoenix)
      G. M. Rubanyi (Richmond)
      T. Sakata (Oita)
      A. Siddiqui (Karachi)
      Cs. Szabo (Beverly)
      E. Vicaut (Paris)
      N. Westerhof (Amsterdam)
      L. F. Zhang (Xi'an)

Editorial Office:
Akadémiai Kiadó Zrt.
Prielle Kornélia u. 21–35, H-1117 Budapest, Hungary

Editorial Correspondence:
Acta Physiologica Hungarica
Semmelweis University, Faculty of Medicine Institute of Pathophysiology
Nagyvárad tér 4, H-1089 Budapest, Hungary
Phone/Fax: +36-1-2100-100
E-mail: aph@semmelweis-univ.hu

Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • Chemical Abstracts
  • EMBASE/Excerpta Medica
  • Global Health
  • Index Copernicus
  • Index Medicus
  • Medline
  • Referativnyi Zhurnal
  • Science Citation Index Expanded
  • SCOPUS

 

Acta Physiologica Hungarica
Language English
Size  
Year of
Foundation
1950
Publication
Programme
changed title
Volumes
per Year
 
Issues
per Year
 
Founder Magyar Tudományos Akadémia
Founder's
Address
H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 0231-424X (Print)
ISSN 1588-2683 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Apr 2021 0 0 0
May 2021 11 1 1
Jun 2021 8 0 0
Jul 2021 2 0 0
Aug 2021 16 0 0
Sep 2021 0 0 0
Oct 2021 0 0 0